Navigation Links
Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II,trial of Cloretazine (VNP40101M) in Patients with Relapsed or,Refractory Small Cell Lung Cancer

NEW HAVEN, Conn., June 04, 2007 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. announced that it presented updated clinical data in a poster session at the 43rd Annual Meeting of The American Society of Clinical Oncology (ASCO) on its lead anticancer agent Cloretazine(R) (VNP40101M) as a single agent in a Phase II trial in patients with relapsed or refractory small cell lung cancer.

The Phase II trial evaluates Cloretazine(R) (VNP40101M) in two separate subpopulations of small cell lung cancer: (i) sensitive relapse disease and (ii) refractory disease. Sensitive relapse disease is defined as relapse after three months of first-line therapy and refractory disease is defined as relapse within three months of first-line therapy. Data are presented on a total of 48 evaluable patients: (i) 20 patients in the sensitive relapse arm and (ii) 28 patients in the refractory arm.

Patients on the trial initially received 125 mg/m2 of Cloretazine(R) (VNP40101M) weekly for three weeks, every six weeks. This dose was later reduced by protocol amendment to 100 mg/m2 weekly for three weeks every six weeks due to the incidence of grade 3 and 4 thrombocytopenia at the initial dose level.

Of the 20 evaluable patients on the sensitive relapse arm, there have been 6 patients with partial response and one patient awaiting confirmation of response (overall, 35% response rate), and 3 patients have stable disease. Four of 13 sensitive relapse patients responded at the 125 mg/m2 dose level and 3 of 7 sensitive relapse patients responded at the 100 mg/m2 dose level. Of the 28 patients with refractory disease treated with Cloretazine(R) (VNP40101M), 1 patient achieved a partial response and 3 patients have demonstrated stable disease.

A total of 55 patients were evaluable for toxicity. Grade 3 and 4 thrombocytopenia was observed in 14 of 31 patients (45%) at the 125 mg/m2 dose level. Thrombocytopenia was su
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:7/22/2014)... July 22, 2014 WuXi PharmaTech (Cayman) Inc. (NYSE: ... device R&D outsourcing company with operations in China ... today announced that it will release financial results for the ... closes on Wednesday, August 13, 2014 (which will be Thursday ... be available on the investor relations section of the Company,s ...
(Date:7/22/2014)... 22, 2014  Pressure BioSciences, Inc. (OTCQB: ... Genomics ("Parabase"), (together "the companies"), today announced ... and development agreement (the "collaboration"). Under the ... a front-end, sample preparation method for Parabase,s ... testing process. The sample preparation method will ...
(Date:7/22/2014)... New York , July 22, ... Neue Partnerschaft für umfassenden Schutz von ... in Österreich    Equashield ... von geschlossenen Transfersystemen (Closed System Transfer Devices, CSTDs) für ... , einen Vertriebshändler und Hersteller von ...
Breaking Medicine Technology:WuXi PharmaTech Schedules Second-Quarter 2014 Earnings Release 2Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 2Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 3Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 4Equashield ernennt Medikus zu seinem exklusiven österreichischen Vertriebspartner für seine geschlossenen Arzneimitteltransfersysteme 2
(Date:7/22/2014)... When it comes to heart disease, Dr. Ross Feldman says ... that heart disease was a men,s-only disease, however, data has ... to get heart disease and are less likely to be ... online this week in the British Journal of Clinical ... disease in women and helps to identify which women are ...
(Date:7/22/2014)... 22, 2014 SIMpalm, a ... payment app for Forte Payment System. Forte Mobile Payment ... payments on iPhone, iPod and iPad. The app ... recently updated by SIMpalm. This update was for iOS ... supported on iOS 4.3 and is available to download ...
(Date:7/22/2014)... The Beryl Institute announces its fifth ... Scholar Program. These offerings reinforce the Institute’s commitment to ... healthcare and the need for rigorous research to understand ... scholar programs are intended to encourage and support ... focusing on the patient experience before, during and after ...
(Date:7/22/2014)... 22, 2014 The park is the ... Kendalltown Homeowners Association, Inc., made a recent ... community with the purchase of playground equipment from American ... in beautiful Miami Florida, and is a 475-unit community ... the surrounding landscape has created a tropical paradise with ...
(Date:7/22/2014)... 2014 (HealthDay News) --,High school lacrosse players are facing ... as games, a new study finds. Although the ... 22 percent are concussions, researchers report. They note a ... lead to better ways to protect student athletes. ... underscores the need to learn more about these injuries," ...
Breaking Medicine News(10 mins):Health News:Gene variant identified as a heart disease risk factor for women 2Health News:SIMpalm Launched Updated Forte Mobile Payment App on iPhone and iPad for Its Client 2Health News:SIMpalm Launched Updated Forte Mobile Payment App on iPhone and iPad for Its Client 3Health News:The Beryl Institute Opens Applications for 2014 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2014 Patient Experience Grant and Scholar Programs 3Health News:Fun in the Florida Sun: Kendalltown Homeowners Association Inc. Expands Outdoor Recreation with American Parks Company™ 2Health News:Fun in the Florida Sun: Kendalltown Homeowners Association Inc. Expands Outdoor Recreation with American Parks Company™ 3Health News:Injuries on the Increase in High School Lacrosse, Study Shows 2Health News:Injuries on the Increase in High School Lacrosse, Study Shows 3
... Presbyterian Hospital of,Plano has been named a recipient ... state,s highest honor for quality and organizational,performance., ... health care facility,in Collin County to receive this ... is the first hospital in parent company Texas ...
... thwarted rewiring needed for neural development, mouse study shows ... class of weight-loss drugs that suppresses appetite by blocking ... caution in children, U.S. scientists report. , In research ... suppresses the adaptive rewiring of the brain necessary for ...
... mice appear perfectly fine without any help from tiny bits ... the retinas do not work. , In the first-ever study ... mammalian eye, an international team of researchers directed by the ... a gradual structural decline in retinas that lack microRNAs ...
... part of its ongoing,commitment to providing the best ... excited to welcome Katherine Anne Binns as Senior ... York office. KN will,draw particularly on her exceptional ... list of clients., "Katherine possesses the expertise ...
... measure breathing patterns in sleeping infants which may also work ... has created a mathematical formula that measures varying breathing patterns ... sleep. , Mr Terrill said a band, placed around ... using the new formula based on the maths of chaos ...
... television ... show., SAN ... campaign to change the image of nursing,in the media. The campaign launches ... the front lines of modern,healthcare. The show, Nurse TV, will premier this ...
Cached Medicine News:Health News:Presbyterian Hospital of Plano Receives Prestigious Texas Award for Performance Excellence 2Health News:MicroRNAs appear essential for retinal health 2Health News:MicroRNAs appear essential for retinal health 3Health News:Senior Researcher With Extensive Healthcare Experience Joins Knowledge Networks 2Health News:Nursing Shortage Spurs Campaign to Change the Image of Nursing in the Media 2
For the quantitative in vitro determination of Transferrin in Serum...
Determination of Reptilase Time.Extracted venom of Bothrops atrox. 20 BU (Batroxobin unit) per vial....
Determination of the Thrombin Time by STA Analyzers. Freeze-dried human thrombin (1.5NIH units/mL) with calcium....
Quantitative determination of Fibrinogen (Clauss Method). Freeze-dried human thrombin (~100NIH units/mL) with heparin inhibitor and calcium....
Medicine Products: